Previous 10 | Next 10 |
2023-05-02 18:38:25 ET Summary Today, we circle back on Geron Corporation for the first time since last summer, as the small biopharma company is moving towards commercialization stage. The company has recently addressed its launch funding needs, has several milestones on the hori...
2023-04-27 11:11:48 ET Summary Geron is planning to submit a New Drug Application (NDA) for imetelstat, a treatment for low to intermediate-1 risk myelodysplastic syndromes (MDS), in 2023 after favorable Phase 3 trial results. Despite a net loss of $141.9 million in 2022, Geron ma...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted ...
2023-04-20 12:18:00 ET Shares of Geron (NASDAQ: GERN) , a clinical-stage biotech company, were up more than 30% this week before CEO John A. Scarlett's scheduled appearance at the Needham Virtual Healthcare Conference on Thursday morning. The stock soared 16% on Wednesday, a...
2023-04-19 14:00:09 ET Geron Corporation ( NASDAQ: GERN ) and CTI BioPharma ( NASDAQ: CTIC ) were among notable gainers in the blood cancer space after an accidental data release from a Phase 3 trial for multiple myeloma therapy Carvykti developed by Legend Biotech ( LEG...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences: 22 nd Annual Needham Vi...
2023-03-28 12:50:23 ET Shares of Geron Corporation ( NASDAQ: GERN ) reached the lowest level since late December on Tuesday after Goldman Sachs launched its coverage with a Neutral view noting that the stock already reflects the commercial prospects of its blood cancer therapy i...
2023-03-24 07:13:27 ET Summary Fate Therapeutics' recent Janssen debacle has brought out comparisons with Geron. However, let's not forget that Geron has never gone back to pre-2019 prices. Fate investors would do well when they rethink their strategy. Fate Therapeut...
2023-03-17 18:16:56 ET Summary Geron announced its Q422 earnings and updated investors on its progress with its only drug Imetelstat yesterday. Imetelstat's positive data in its Phase 3 in low-risk MDS sets up approval shots in the US and Europe. Management is talking up a blo...
2023-03-16 20:53:40 ET The following slide deck was published by Geron Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Geron Corporation 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...